Q-omics provides the consensus-scored TBL3 profile across patient tissues and cancer cell-line models. TBL3 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, TBL3 is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, TBL3 protein abundance shows 32,961 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, COAD, and LSCC as cancer lineages where TBL3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TBL3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TBL3 survival associations across molecular data types. TBL3 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (6) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TBL3 RNA expression–survival associations across cancer types. High TBL3 expression shows unfavorable associations in ACC, MESO and BLCA, but favorable associations in SCLC, READ and UVM. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .006). Together, the overview and detailed table identify ACC as the clearest survival context for TBL3 RNA expression.
This table summarizes TBL3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TBL3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TBL3 shows higher tumor expression in COAD, KIRP, KIRC, LIHC, STAD and LUSC. The COAD box plot shows higher TBL3 RNA expression in tumor versus normal tissue (log2 FC = +1.263, t-test p < 0.001).
This table shows molecular features associated with TBL3 in patient tissues and cancer cell lines. In patient samples, TBL3 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, TBL3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and UPPER_AERODIGESTIVE_TRACT.
